Evidence map›Paper›PMID 37487481›Full record

SynthesisNeonatology2023

A Meta-Analysis of Neurodevelopmental Outcomes following Intravitreal Bevacizumab for the Treatment of Retinopathy of Prematurity.

Abed A Baiad, Imaan Z Kherani, Marko M Popovic, Glen Katsnelson, Rajeev H Muni, Kamiar Mireskandari, Nasrin N Tehrani, Tianwei Ellen Zhou, Peter J Kertes

Open access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neonatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Abed A BaiadFaculty of Medicine and Health Sciences, McGill University, Montreal, Québec, Canada, abd.baiad@mail.mcgill.ca.
Imaan Z KheraniTemerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Marko M PopovicDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Glen KatsnelsonTemerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Rajeev H MuniDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Kamiar MireskandariDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Nasrin N TehraniDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Tianwei Ellen ZhouDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Peter J KertesDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
University of Toronto · CAMcGill University Health Centre · CASt. Michael's Hospital · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinopathy of prematurity (ROP) is the most common cause of preventable blindness in preterm infants. First-line treatments include intravitreal bevacizumab (IVB) or laser photocoagulation (LPC).

objectivesThe aim of the study was to evaluate neurodevelopmental safety of IVB compared to LPC for ROP.

methodsMEDLINE, Embase, and Cochrane library were searched up to September 2022. Studies were included with at least 12-month follow-up of primary outcomes such as severe neurodevelopmental impairment (sNDI), cerebral palsy (CP), and hearing impairment (HI). Secondary outcomes were moderate-to-severe neurodevelopmental impairment (msNDI), Bayley Scores of Infant Development (BSID-III), and visual impairment.

results1,231 patients from 11 comparative studies were included. Quality of evidence was rated low for all outcomes. IVB was associated with a higher risk for sNDI (risk ratio [RR] = 1.25, 95% confidence interval [CI]: [1.01, 1.53], p = 0.04); and CP (RR = 1.40, CI: [1.08, 1.81], p = 0.01) compared to LPC. There was no significant difference between IVB and LPC for msNDI (RR = 1.15, CI: [0.98, 1.35], p = 0.08) and HI (RR = 1.43, CI: [0.86, 2.39], p = 0.17). BSID-III percentile scores were similar between IVB and LPC, with weighted mean differences of 1.51 [CI = -1.25, 4.27], 2.43 [CI = -1.36, 6.22], and 1.97 [CI = -1.06, 5.01] for cognitive, language, and motor domains, respectively (p > 0.05).

conclusionTo our knowledge, this is the largest meta-analysis on neurodevelopmental outcomes and the first to rigorously examine IVB monotherapy in ROP treatment. Compared to LPC, there was a marginally increased risk for sNDI and CP with IVB but little or no difference in the risk of msNDI and HI. Further randomized studies are needed to strengthen these findings.

Indexed as

Infant, PrematureRetinopathy of PrematurityAngiogenesis InhibitorsBevacizumabChildChild DevelopmentHumansInfantInfant, NewbornRetrospective StudiesAngiogenesis InhibitorsBevacizumabDevelopmentNeurodevelopmentPreterm infantRetinopathy of prematurityVascular endothelial growth factor

Identifiers

PMID37487481
PMCPMC10777715
OpenAlexW4385230605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.